World Health Organization site
Skip Navigation Links

Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: ClinicalTrials.gov
Last refreshed on: 16 December 2017
Main ID:  NCT01882543
Date of registration: 18/06/2013
Prospective Registration: No
Primary sponsor: Aquinox Pharmaceuticals (Canada) Inc.
Public title: Efficacy and Safety of AQX-1125 in IC/BPS LEADERSHIP
Scientific title: A Phase 2 Study to Evaluate the Efficacy and Safety of AQX-1125 in Subjects With Interstitial Cystitis/Bladder Pain Syndrome Mediated by the Src Homology-2-domain-containing Inositol 5' Phosphatase [SHIP1] Pathway
Date of first enrolment: June 2013
Target sample size: 69
Recruitment status: Completed
URL:  https://clinicaltrials.gov/show/NCT01882543
Study type:  Interventional
Study design:  Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).  
Phase:  Phase 2
Countries of recruitment
Canada United States
Contacts
Name:     Stephen B Shrewsbury, MD
Address: 
Telephone:
Email:
Affiliation:  Aquinox Pharmaceuticals (Canada) Inc.
Key inclusion & exclusion criteria

Inclusion Criteria:

- Be females, =18 and =75 years of age, who have consistently had symptoms of bladder
pain in addition to urinary urgency and/or urinary frequency for more than 12 months

- Have had the diagnosis of interstitial cystitis for > 6 months (pain for at least 12
months) but =15 years

- Have average daily pain score of at least 5 out of 10 on the 11-point Numerical Rating
Scale [NRS] pain scale in the 9 days prior to baseline

- Have undergone a cystoscopy and have documented visible signs of bladder bleeding,
lesions or glomerulation within the last 36 months prior to baseline.

- Subjects if of child bearing potential, must agree to avoid pregnancy and use
medically acceptable method of contraception from screening visit and throughout the
study.

- Must be capable of voiding independently

Exclusion Criteria:

- Pelvic floor pain (>5 out of 10 on the 11-point NRS pain scale following a pelvic pain
assessment)

- Have a body mass index [BMI] of <18 kg/m2 or >39 kg/m2

- Have had a urinary tract infection including bacterial cystitis within the past 30
days.

- Have greater than 1+ hematuria on dipstick test at screening from an unknown cause

- History of previous procedure(s) (augmentation cystoplasty, cystectomy, or cystolysis)
that has affected bladder function



Age minimum: 18 Years
Age maximum: 75 Years
Gender: Female
Health Condition(s) or Problem(s) studied
Interstitial Cystitis
Bladder Pain Syndrome
Intervention(s)
Drug: AQX-1125
Drug: Placebo
Primary Outcome(s)
Change From Baseline in the Average Daily Bladder Pain Score (e-Diary) [Time Frame: Baseline to Week 6]
Secondary Outcome(s)
Bladder Pain/Interstitial Cystitis Symptom Score [BPIC-SS] [Time Frame: Baseline to Week 6]
Change From Baseline in the Maximum Bladder Pain Score (Clinic) [Time Frame: Baseline to Week 6]
Change From Baseline in the Average Bladder Pain Score (Clinic) [Time Frame: Baseline to Week 6]
Voiding Frequency as Recorded by Diary Over a 24 Hour Period [Time Frame: Baseline to Week 6]
Change From Baseline in the Maximum Daily Bladder Pain Score (e-Diary) [Time Frame: Baseline to Week 6]
O'Leary-Sant Interstitial Cystitis Symptom Index/Problem Index [ICSI/PI] [Time Frame: Baseline to Week 6]
Short Form 12 Version 2.0 Health Survey [SF-12v2] Questionnaire [Time Frame: Baseline to Week 6]
Secondary ID(s)
AQX-1125-201
Source(s) of Monetary Support
Please refer to primary and secondary sponsors
Secondary Sponsor(s)
Ethics review
Results
Results available: Yes
Date Posted: 05/09/2017
Date Completed:
URL: https://clinicaltrials.gov/ct2/show/results/NCT01882543
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history